多中心研究:用于移行区PI-RADS 3和4病变检出临床显著前列腺癌的双参数磁共振聚焦模型的开发与验证
本研究为多中心回顾性队列分析,开发并外部验证了针对移行区PI-RADS 3和4病变、用于检出临床显著前列腺癌(Gleason评分≥7)的双参数磁共振聚焦模型,并与基于风险的模型(PI-RADS≥3且PSA密度≥0.15 ng/ml/cm³)进行比较。结果显示双参数磁共振聚焦模型在开发队列和外部验证队列中的AUC均高于基于风险的模型,并显著减少假阳性,同时保持与PI-RADS≥3策略相当的癌症检出率;作者结论认为可将移行区PI-RADS 3或4病变纳入该模型以减少不必要的活检。
要点
- 双参数磁共振聚焦模型在开发队列AUC 0.71(95%CI 0.62-0.81),外部验证队列AUC 0.75(95%CI 0.63-0.87)。
- 基于风险模型在开发队列AUC 0.83(95%CI 0.74-0.92),外部验证队列AUC 0.87(95%CI 0.79-0.95)。
- 双参数磁共振聚焦模型假阳性54例(23%)vs 基于风险模型142例(61%),p<0.002。
核心结论
- 在临床决策中,可将移行区PI-RADS 3或4病变纳入双参数磁共振聚焦模型以减少不必要的活检。
研究设计与样本
- 多中心回顾性队列分析,开发队列(队列1)纳入121例患者共231个病变,外部验证队列(队列2)纳入45例患者共81个病变,纳入时间为2020年1月至2024年12月,纳入连续患者且PI-RADS 3或4并有合格活检结果;采用多变量logistic回归筛选临床显著前列腺癌预测因子,比较双参数磁共振聚焦模型与基于风险模型(PI-RADS≥3且PSA密度≥0.15 ng/ml/cm³)的AUC和决策曲线分析,并进行外部验证。
诊断标准与关键数值
- 临床显著前列腺癌定义为Gleason评分≥7;基于风险模型标准为PI-RADS≥3且PSA密度≥0.15 ng/ml/cm³;双参数磁共振聚焦模型开发队列AUC 0.71(95%CI 0.62-0.81),外部验证队列AUC 0.75(95%CI 0.63-0.87);基于风险模型开发队列AUC 0.83(95%CI 0.74-0.92),外部验证队列AUC 0.87(95%CI 0.79-0.95);两模型AUC比较均p<0.05。
临床应用与阅片要点
- 作者结论认为,在临床决策中可将移行区PI-RADS 3或4病变纳入双参数磁共振聚焦模型以减少不必要的活检。
局限性
- 双参数磁共振聚焦模型避免活检率15例(6%)vs 基于风险模型10例(4%),差异无统计学意义(p=0.30)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop and validate a biparametric magnetic resonance imaging(BpMRI) focused model for detecting clinically significant prostate cancer(csPCa)( Gleason score ≥ 7) in TZ PI-RADS 3 and 4 lesions, compared to the Risk-based model (PI-RADS ≥ 3 and PSA density (PSAD) ≥ 0.15 ng/ml/cm³).
METHODS: A multi-center, retrospective cohort analysis was conducted on consecutive patients with PI-RADS 3 or 4 and eligible biopsy result. Multivariable logistic regression identified predictors of csPCa, followed by the areas under the curve(AUC) and decision curve analysis (DCA) comparisons between the Risk-based and BpMRI focused models, with external validation.
RESULTS: A total of 121 patients with 231 lesions in the development cohort(cohort 1) and 45 patients with 81 lesions the external validation cohort(cohort 2) were included between January 2020 and December 2024. The AUCs of the BpMRI-focused model were higher than those of the risk-based model in both the development cohort (0.71 [95% CI: 0.62-0.81] vs. 0.83 [95% CI: 0.74-0.92], p < 0.05) and the external validation cohort (0.75 [95% CI: 0.63-0.87] vs. 0.87 [95% CI: 0.79-0.95], p < 0.05). Furthermore, the BpMRI Focused Model significantly reduced the number of false positives for clinically significant prostate cancer compared to the Risk-Based Model [54 (23%) vs. 142 (61%), p < 0.002], while maintaining a cancer detection rate comparable to the PI-RADS ≥ 3 strategy (both p > 0.05). Additionally, the BpMRI Focused Model achieved a higher biopsy avoidance rate for csPCa [15 (6%)] compared to the Risk-Based Model [10 (4%)], though the difference was not statistically significant (p = 0.30).
CONCLUSION: In clinical decision-making, lesions in the TZ with PI-RADS 3 or 4 can be incorporated into the BpMRI focused model to reduce unnecessary biopsies.
引用
- Yi Y, Chen Z, Wang H, et al. A multi-center study: development and validation of a BpMRI focused model in transition zone PI-RADS 3 and 4 lesions to detect clinically significant prostate cancer. Abdom Radiol (NY). 2025. PMID: 40317358. doi:10.1007/s00261-025-04974-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。